Explore 3 Stock Ideas & Industry Insights Download Free Report

800-234-336
Shopping Cart 0
countryflagNZ
Login

Chimerix Inc

Healthcare US CMRX

NoneUSD
0.00(0%)

Last update at 2025-05-19T13:04:15.594709Z

Day Range

--
LowHigh

52 Week Range

0.753.39
LowHigh

Fundamentals

  • Previous Close -
  • Market Cap77.79M
  • VolumeNone
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-92.73500M
  • Revenue TTM0.16M
  • Revenue Per Share TTM0.002
  • Gross Profit TTM -36.48600M
  • Diluted EPS TTM-0.94

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax 172.20M -173.23600M -43.52200M -112.57600M -69.47400M
Minority interest - - - - -
Net income 172.17M -255.79500M -42.12600M -173.65000M -69.47400M
Selling general administrative 22.13M 18.67M 13.66M 21.17M 23.58M
Selling and marketing expenses - - - - -
Gross profit 33.38M 1.98M 5.37M 12.52M 7.22M
Reconciled depreciation 0.10M 0.17M 0.40M 0.56M 0.86M
Ebit -60.38600M -173.40000M -44.91800M 13.54M -72.11700M
Ebitda -290.05600M -7.62000M -44.51600M 14.11M -71.25700M
Depreciation and amortization -229.67000M 165.78M 0.40M 0.56M 0.86M
Non operating income net other 229.67M - - - -
Operating income -60.38600M -173.40000M -44.51600M 13.54M -71.60500M
Other operating expenses 94.21M 92.49M 49.89M 63.46M 78.82M
Interest expense 2.92M 165.61M 0.99M 0.00000M 2.48M
Tax provision 0.04M - - - -
Interest income 2.92M 0.16M 0.99M 3.41M 2.48M
Net interest income 2.92M 0.16M 0.99M 3.41M 2.48M
Extraordinary items - - - - -
Non recurring - 82.89M - 65.05M -
Other items - - - - -
Income tax expense 0.04M 82.56M -1.39600M 61.07M 2.13M
Total revenue 33.82M 1.98M 5.37M 12.52M 7.22M
Total operating expenses 93.76M 92.49M 49.89M 63.46M 78.82M
Cost of revenue 0.45M - - 38.49M 55.24M
Total other income expense net 232.59M 0.16M 0.99M -126.11900M -0.34800M
Discontinued operations - - - - -
Net income from continuing ops 172.17M -173.23600M -43.52200M -112.57600M -69.47400M
Net income applicable to common shares 172.17M -173.23600M -43.52200M -112.57600M -69.47400M
Preferred stock and other adjustments - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 212.77M 279.34M 100.54M 84.72M 119.38M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 5.04M 9.76M 4.68M 2.36M 3.38M
Total liab 19.75M 22.48M 32.29M 11.35M 9.42M
Total stockholder equity 193.03M 256.86M 68.25M 73.38M 109.95M
Deferred long term liab - 0.30M - - -
Other current liab 14.75M 17.38M 13.11M 7.25M 6.83M
Common stock 0.09M 0.09M 0.09M 0.06M 0.06M
Capital stock 0.09M 0.09M 0.09M 0.06M 0.06M
Retained earnings -795.52400M -713.42900M -885.59600M -712.36000M -668.83800M
Other liab - 0.25M - - -
Good will - - - - -
Other assets - 0.39M 0.06M 2.85M 0.03M
Cash 27.66M 25.84M 15.40M 46.99M 16.90M
Cash and equivalents - - - - -
Total current liabilities 18.44M 20.41M 29.90M 8.53M 9.23M
Current deferred revenue - - - - -
Net debt -25.51700M -23.77300M 0.99M -44.17500M -16.70500M
Short term debt 0.84M - 14.00M 4.30M -
Short long term debt - - 14.00M - -
Short long term debt total 2.14M 2.07M 16.39M 2.81M 0.20M
Other stockholder equity 988.46M 970.53M 953.78M 785.67M 778.69M
Property plant equipment - 0.23M 2.66M 0.21M 0.54M
Total current assets 189.01M 228.14M 95.81M 81.66M 118.09M
Long term investments 21.66M 48.63M 2.02M - -
Net tangible assets - 256.86M 68.25M 73.38M 109.95M
Short term investments 155.17M 191.49M 72.97M 31.97M 96.57M
Net receivables 1.14M 1.04M 0.35M 0.34M 1.23M
Long term debt 0.12M 0.25M - - -
Inventory - 0.00000M 2.76M - -
Accounts payable 2.85M 3.03M 2.79M 1.28M 2.40M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 0.00700M -0.33700M -0.02100M - 0.04M
Additional paid in capital - - - - -
Common stock total equity - 0.09M 0.09M 0.06M 0.06M
Preferred stock total equity - - - - -
Retained earnings total equity - -713.42900M -885.59600M -712.36000M -668.83800M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.40M 0.39M 0.06M 0.03M 0.03M
Deferred long term asset charges - - - - -
Non current assets total 23.76M 51.20M 4.74M 3.06M 1.28M
Capital lease obligations 1.18M 1.82M 2.39M 2.81M 0.20M
Long term debt total - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -163.87600M -43.88400M 64.76M 10.79M 105.28M
Change to liabilities 5.50M 7.06M -0.18600M -4.29400M 0.00500M
Total cashflows from investing activities 70.04M -44.09100M 64.71M 10.63M 105.09M
Net borrowings -14.00000M -14.00000M -14.00000M -14.00000M -
Total cash from financing activities -12.72500M 112.43M 1.41M 0.34M 11.19M
Change to operating activities -5.41900M -2.35200M 1.02M -0.77700M 0.64M
Net income 172.17M -173.23600M -43.52200M -112.57600M -69.47400M
Change in cash 10.45M -31.59200M 30.09M -64.20500M 62.56M
Begin period cash flow 15.40M 46.99M 16.90M 81.11M 18.55M
End period cash flow 25.84M 15.40M 46.99M 16.90M 81.11M
Total cash from operating activities -46.86700M -99.93000M -36.03800M -75.18100M -53.72500M
Issuance of capital stock 0.00000M 107.84M 0.00000M - 10.87M
Depreciation 0.10M 0.17M 0.40M 0.56M 0.86M
Other cashflows from investing activities 233.98M - 0.01000M 10.79M 105.28M
Dividends paid - - - - -
Change to inventory -2.46700M -2.76000M 0.19M 4.29M -0.00500M
Change to account receivables -1.04000M 0.34M 0.89M -0.90300M 1.35M
Sale purchase of stock 1.27M 112.43M 1.41M 0.34M 11.19M
Other cashflows from financing activities 0.67M 4.59M 1.41M -34.55500M 0.32M
Change to netincome -214.38600M 12.26M 5.55M 44.72M 13.45M
Capital expenditures 0.07M 0.21M 0.06M 0.16M 0.18M
Change receivables -1.04000M 0.34M 0.89M -0.90300M 1.35M
Cash flows other operating -5.41000M 55.39M 1.01M -0.85300M 0.93M
Exchange rate changes - - - - -
Cash and cash equivalents changes 10.45M -31.59200M 30.09M -64.20500M 62.56M
Change in working capital -3.42200M 2.29M 1.73M -5.97400M 2.00M
Stock based compensation 15.29M 12.26M 5.57M 9.53M 13.07M
Other non cash items -230.99500M 57.75M -0.01400M 34.82M -0.05900M
Free cash flow -46.93800M -100.13700M -36.09600M -75.33900M -53.90600M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
CMRX
Chimerix Inc		 - -% - - 1.21 489.27 0.55 3.57 1.03
NVO
Novo Nordisk A/S		 1.81 4.32% 43.81 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 1.78 4.23% 44.00 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 12.68 2.96% 441.01 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 6.44 1.04% 625.39 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Chimerix, Inc., a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors. The company also develops ONC212, an imipridone agonist of the orphan G protein-coupled receptors (GPCR) tumor suppressor GPR132, as well as ClpP for oncology indications; and CMX521, a nucleoside analog antiviral drug candidate for the treatment of SARS-CoV-2. It has license agreement with SymBio Pharmaceuticals to develop and commercialize TEMBEXA for human diseases other than orthopoxviruses, including smallpox. Chimerix, Inc. was incorporated in 2000 and is headquartered in Durham, North Carolina.

Chimerix Inc

2505 Meridian Parkway, Durham, NC, United States, 27713

Key Executives

Name Title Year Born
Mr. Michael A. Sherman M.B.A. CEO, Pres & Director 1966
Mr. Michael T. Andriole M.B.A. Chief Bus. Officer, Sec. & CFO 1973
Dr. Allen S. Melemed M.B.A., M.D. Chief Medical Officer 1964
Mr. David Jakeman CPA Exec. Director of Fin. & Accounting and Principal Accounting Officer 1978
Dr. Roy W. Ware Chief Manufacturing & Technology Officer NA
Dr. Randall Lanier Chief Science Officer NA
Ms. Michelle LaSpaluto VP of Strategic Planning & Investor Relations NA
Dr. Michael A. Alrutz Sr. VP, Gen. Counsel & Corp. Sec. 1970
Dr. Joshua E. Allen Chief Technology Officer of Imipridones NA
Mr. Michael T. Andriole M.B.A. CEO, President & Director 1973

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.